SCHEMBL6488640

SCHEMBL6488640

O=C(Nc1ccc(N2CCN(Cc3nccs3)CC2)cc1)C1=C(c2ccc(C(F)(F)F)cc2)CCCC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRPK1 Q96SB4 3/20 0.51
HIF1A Q16665 7/20 0.46
EPAS1 Q99814 7/20 0.46
NR3C1 P04150 2/20 0.45
KCNH2 Q12809 1/20 0.43
LCK P06239 1/20 0.42
HCK P08631 1/20 0.42
SRC P12931 1/20 0.42
KDR P35968 1/20 0.42
MAPKAPK2 P49137 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
USP2 O75604 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
MTTP P55157 1/20 0.40
SMO Q99835 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491879 0.84 HIF1A (0.46) HIF1AEPAS1KCNH2LCKHCK
SCHEMBL6490877 0.84 MTTP (0.45) SRPK1HIF1AEPAS1NR3C1KDR
SCHEMBL6490805 0.83 HIF1A (0.64) HIF1AEPAS1USP2
SCHEMBL6499822 0.83 MAPKAPK2 (0.46) HIF1AEPAS1KCNH2LCKHCK
SCHEMBL6490755 0.82 CA1 (0.51) HIF1AEPAS1KCNH2MAPKAPK2CA1
SCHEMBL6499289 0.81 SRPK1 (0.51) SRPK1HIF1AEPAS1KCNH2MAPKAPK2
SCHEMBL6501481 0.81 CA1 (0.52) HIF1AEPAS1KCNH2LCKHCK
SCHEMBL6490778 0.80 MAPKAPK2 (0.46) HIF1AEPAS1KCNH2LCKHCK
SCHEMBL6492808 0.80 HIF1A (0.46) SRPK1HIF1AEPAS1KCNH2MAPKAPK2
SCHEMBL6503264 0.80 HTR1A (0.51) HIF1AEPAS1KCNH2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 SRPK1 3887/4885HIF1A 2476/4885EPAS1 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.